Communicators

are winners!

News

08.04.2019
Medigene AG: Medigene participates at upcoming conferences

Medigene AG: Medigene participates at upcoming conferences

 

Business news for the stock market

 

Martinsried/Munich (08.04.2019/07:30) - Medigene AG (FSE: MDG1, Prime Standard) today announced its participation at the following upcoming networking and scientific conferences:

 

Deutsche Biotechnologietage 2019

Date: 09 - 10 April 2019

Location: Würzburg, Germany

 

Dr Kai Pinkernell, Chief Medical Officer (CMO) and Chief Development Officer (CDO) of Medigene AG, will give a talk entitled "Developments of T cell therapies in the field of Immunotherapies" during the symposium "Experiences with gene therapeutics - from development to approval" on 10 April 2019 from 11.30 am to 13.00 pm.

 

Needham & Company 18th Annual Healthcare Conference 2019

Date: 09 - 10 April 2019

Location: New York, USA

Prof. Dolores J. Schendel, CEO of Medigene AG, will give a company presentation on 10 April 2019 at 4.10 pm.

 

ITOC6 Conference

Date: 11 - 13 April 2019

Location: Vienna, Austria

 

3rd Annual European NeoAg Summit

Date: 23 - 25 April 2019

Location: Amsterdam, Netherlands

 

22nd ASGCT Annual Meeting

Date: 29 April - 02 May 2019

Location: Washington, USA

 

Dr Maja Buerdek, Director Cellular Tools at Medigene, will give an oral presentation on the topic "In Vitro Evaluation of Potential PRAME TCR-Mediated Off-Target Toxicity Using iPSC-Derived Neuronal Cells" on 30 April 2019 from 5.00pm - 5.15pm in the session Nonclinical Studies and Assay Development.

 

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

 

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

 

Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer

Tel.: +49 - 89 - 20 00 33 - 33 01,

email: investor@medigene.com

 

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

 

(end)

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg

country: Germany

contact person: Medigene PR/IR

phone: +49 89 2000 33 3301

e-mail: investor@medigene.com

website: www.medigene.de

ISIN(s): DE000A1X3W00 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

 

 



NEWSLETTER REGISTRIERUNG:



Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
Newsletter...

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.

Kostenloser Abdruck mit Quellenangabe erlaubt.